Miami, Florida, 33014, United States
NCT Number: NCT02095587
Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects
To evaluate the pharmacokinetics, safety, and tolerability of IPI-145 when administered to subjects with chronic hepatic impairment and in matched healthy subjects.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–70 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 1
Primary location
About this study
This is a nonrandomized, open-label, parallel-group, single oral dose study in subjects with chronic hepatic impairment and matched (age, sex, weight, BMI) healthy subjects. Subjects will be enrolled into 1 of 3 groups based on hepatic impairment grade: mild, moderate and normal hepatic function. An optional severe hepatic impairment group will enroll based on data from the mild and moderate hepatic impairment groups in comparison to matched healthy group. All subjects will receive a single oral dose of IPI-145 25 mg.
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Men or women of nonchildbearing potential between 18-70 years of age
- Body Mass Index (BMI): 18.0 - 38.0 kg/m2.
- Healthy subjects: in good health, determined by no clinically significant findings from clinical evaluations
- Hepatic impairment subjects: confirmed hepatic impairment >1 year with etiology of chronic alcoholism, chronic viral hepatitis (B or C), nonalcoholic steatohepatitis, autoimmune hepatitis, Wilson disease, alpha-1 antitrypsin deficiency, glycogen storage diseases, or galactosemia
- Provided written informed consent prior to any study specific procedures
Exclusion criteria
- Women of childbearing potential
- Hepatic impairment subjects: fluctuating or rapidly deteriorating hepatic function, acute hepatitis, variceal bleeding within 8 weeks of screening, a history of pancreatitis within 8 weeks of screening, evidence of hepatic encephalopathy > Grade 1, current unstable hematologic condition, and/or creatinine clearance < 60 mL/min
- Healthy subjects: positive screening test for hepatitis B surface antigen, or hepatitis C antibody
- ECG at screening or Day -1 showing QTcF ≥ 450 msec for healthy subjects or > 500 msec for hepatically impaired subjects
- Evidence of clinically significant medical conditions
- History of gastrointestinal disease or surgery that may affect drug absorption
- Positive or indeterminate QuantiFERON-TB Gold test at screening
- Any active infection at the time of screening or admission
Treatment and study plan
IPI-145
Drug25 mg single oral capsule
Primary outcomes
-
Pharmacokinetic parameters of IPI-145 and its primary metabolite, IPI-656
Time frame: Open 72 hours
PK parameters (AUC, Cmax and t1/2) of IPI-145 and its metabolite, IPI-656 Plasma concentrations of IPI-145 and its metabolite, IPI-656
Secondary outcomes
-
Incidence of adverse events following administration of IPI-145
Time frame: 10 days
Safety Findings
Sponsors and collaborators
Lead sponsor
SecuraBio
Industry
Registry information
Official study title
A Phase 1, Open-Label, Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Dose of Duvelisib in Subjects With Chronic Hepatic Impairment Compared to Healthy Subjects
Acronym: IPI-145-14
Important dates
- Study start
- 2014
- Primary completion
- 2014
- Study completion
- 2014
- First posted
- Mar 26, 2014
- Registry last updated
- Mar 17, 2021
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
NCT06911320
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Orlando, Florida, United States
View Trial DetailsPharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment
NCT03289234
Healthy, Hepatic Impairment
Fukuoka, Japan
View Trial DetailsGT-032 Belapectin Hepatic Impairment
NCT04332432
Hepatic Impairment
Rialto, California, United States
View Trial DetailsPharmacokinetics, Safety and Tolerability of ITF2357 in Participants With Chronic Hepatic Impairment and With Normal Hepatic Function
NCT06736223
Hepatic Impairment
Sofia, Bulgaria
View Trial Details